Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious dise… Read more
Revive Therapeutics Ltd (RVVTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.034x
Based on the latest financial reports, Revive Therapeutics Ltd (RVVTF) has a cash flow conversion efficiency ratio of -0.034x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-217.58K) by net assets ($6.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Revive Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Revive Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Revive Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revive Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kelso Technologies Inc
PINK:KIQSF
|
0.066x |
|
CGX Energy Inc
PINK:CGXEF
|
-0.235x |
|
NuGen Medical Devices Inc
OTCQB:NGMDF
|
0.122x |
|
Sammakorn Public Company Limited
BK:SAMCO
|
-0.017x |
|
Proodeftiki S.A.
AT:PRD
|
-0.022x |
|
Compremum S.A.
WAR:CPR
|
0.007x |
|
Duniec
TA:DUNI
|
-0.039x |
|
ABS-CBN Holdings Corporation
PINK:ABSOF
|
N/A |
Annual Cash Flow Conversion Efficiency for Revive Therapeutics Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Revive Therapeutics Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $7.23 Million | $-3.29 Million | -0.455x | +19.56% |
| 2023-06-30 | $10.65 Million | $-6.03 Million | -0.566x | +45.42% |
| 2022-06-30 | $12.60 Million | $-13.06 Million | -1.036x | -259.38% |
| 2021-06-30 | $28.81 Million | $-8.31 Million | -0.288x | +14.84% |
| 2020-06-30 | $7.43 Million | $-2.52 Million | -0.339x | +72.54% |
| 2019-06-30 | $960.78K | $-1.18 Million | -1.233x | +32.42% |
| 2018-06-30 | $821.12K | $-1.50 Million | -1.825x | -41.62% |
| 2017-06-30 | $1.62 Million | $-2.08 Million | -1.289x | +63.12% |
| 2016-06-30 | $568.64K | $-1.99 Million | -3.494x | -452.58% |
| 2015-06-30 | $2.36 Million | $-1.49 Million | -0.632x | -4.07% |
| 2014-06-30 | $1.19 Million | $-720.14K | -0.607x | -- |